Dear Colleagues, Sana Al Sukhun, MD, MSc. JOS president.

Size: px

Start display at page:

Download "Dear Colleagues, Sana Al Sukhun, MD, MSc. JOS president."

Laureen Tucker
5 years ago
Views:

Dear Colleagues, On behalf of the Jordanian Oncology Society Executive Committee, it is my pleasure to welcome you to the "Highlights of ASCO " conference at the Movenpick Dead Sea Hotel.

1 Dear Colleagues, On behalf of the Jordanian Oncology Society Executive Committee, it is my pleasure to welcome you to the "Highlights of ASCO " conference at the Movenpick Dead Sea Hotel. We will be reviewing the most important, practice changing data presented at ASCO, and particularly how the results may change the current standard of care. It will also be a good opportunity for us, especially colleagues who were not able to attend the ASCO meeting, to discuss the clinical implications of the presented data within the current standards of care in an interactive setting. We wish you a fruitful enjoyable experience and look forward to your active participation. Sincerely, Sana Al Sukhun, MD, MSc. JOS president.

Improving Health Outcomes through Education & Collaboration Schedule at a Glance 6:30pm - 7:00pm Registration and Reception 7:00pm - 7:10pm Welcome & Chair remarks.

2 Improving Health Outcomes through Education & Collaboration Schedule at a Glance 6:30pm - 7:00pm Registration and Reception 7:00pm - 7:10pm Welcome & Chair remarks. 7:10pm - 7:40pm Keynote Talk 7:40pm - 8:30pm Patient and Survivor Care 9:00 pm - 11:00 pm Dinner Thursday July 30 9:00am - 10:00am Lung Cancer Non-Small Cell 10:00am -11:00am Breast Cancer-Targeted therpy 11:00am - 11:15am 11:15am - 11:30am Friday Breast Cancer-Cytotoxic Chemotherapy 11:30am - 12:10pm Breast Cancer-Local Therapy 12:10pm - 2:30pm Lunch and Friday prayers. 02:30pm- 3:00pm Gastrointestinal (Colorectal) Cancer 03:00pm - 03:40pm Gastrointestinal (Noncolorectal) Cancer 03:40pm - 04:00pm 04:00pm - 05:15am Melanoma, Skin cancer. 08:00pm -10:00pm Dinner 9:00am - 10:00am Saturday Head and Neck Cancer August 01 10:00am - 10:35am Genitourinary (Prostate) Cancer 10:35am - 11:00am 11:00am - 12:00pm Lymphoma and Plasma Cell Disorders

and Abdallah Abbadi, MD 7:10pm - 7:40pm The promise of immunotherapy in lung cancer Speaker: Rolf Stahel, MD 7:40pm - 7:50pm Rolf Stahel, MD ESMO President 7:50pm - 8:30pm Patient and Survivor Care

3 Thursday July 30 6:30pm - 7:00pm 7:00pm - 7:10pm 7:10pm - 7:50pm Registration and Reception Welcome & Chair remarks. Speaker: Sana Al Sukhun, MD, MSc Sana Al Sukhun, MD, MSc JOS President Keynote Talk Moderators : Sana Al Sukhun, MD, MSc. and Abdallah Abbadi, MD 7:10pm - 7:40pm The promise of immunotherapy in lung cancer Speaker: Rolf Stahel, MD 7:40pm - 7:50pm Rolf Stahel, MD ESMO President 7:50pm - 8:30pm Patient and Survivor Care Moderators : Ahmad Telfah, MD and Fayez Tbeishat, MD 7:50pm - 8:05pm 8:05pm - 8:20pm 8:20pm - 8:30pm Speaker: Sameh Hashem, MD Abstract 8005: Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN ). (Paula Mary Mulvenna). Abstract LBA4: NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. (Paul Brown). Speaker: Mohammad Salameh, MD Abstract 9501: CALGB (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. (Andrew Louis Abstract 504: Adjuvant denosumab in breast cancer: Results from 3,425 postmeno pausal patients of the ABCSG-18 trial. (Michael Gnant). Himelstein) Thursday July 30 9:00pm - 11:00pm Dinner

4 Friday 9:00am - 10:00am Lung Cancer Non-Small Cell Moderators : Fadi Farhat, MD and Kholoud Al-qasem, MD 9:00am - 9:45am Speaker: Rolf Stahel, MD Abstract 8001: Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). (Lecia V. Sequist) Abstract 8006: Interim results of a phase 2 study of the BRAF inhibitor (BRAFi) \dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). (David Planchard) Abstract 7500: Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701MAPS randomized phase 3 trial. (Gerard Zalcman) Abstract 7506: Final overall survival (OS) results of the phase III PROCLAIM trial:pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsnsclc).(suresh Senan) 10:00am - 11:00am Abstract 7507: Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels inpatients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract: ; NCTgov: ). (Bartomeu Massuti) 9:45am - 10:00am Breast Cancer-Targeted Therapy Moderators : Salah Abbasi, MD and Sami Rabadi, MD 10:00am - 10:30am Speaker: Sana Al Sukhun, MD, MSc. Abstract LBA502: PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. (Nicholas Turner) Abstract 507: Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. (Paul Anthony Ellis). receptor negative early breast cancer. (Marco Colleoni) Friday

5 Friday 11:00am - 11:15am 11:15am - 11:30am 10:30am - 10:45am 10:45am - 11:00am Abstract 508: Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). (Arlene Chan). Speaker: Hazem Abdulellah, MD Abstract 1003: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). (Tiffany A. Traina). Breast Cancer-Cytotoxic Chemotherapy Moderators : Tahseen Al-Rubaie, MD 11:15am - 11:30am Speaker: Fadi Farahat, MD Abstract 1001: Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician s Choice (TPC) in patients with advanced breast cancer (abc) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACONstudy. (Edith A. Perez) 11:30am - 12:10pm 12:10pm - 2:30pm Lunch and Friday prayers Abstract 1002: Low dose oral cyclophosphamide-methotrexate maintenance for receptor negative early breast cancer. (Marco Colleoni) Breast Cancer-Local Therapy Moderators : Mahmoud Al Masri, MD and Sami Khatib, MD 11:30am - 11:45am Speaker: Mohammed Basem Hamdan, MD Abstract 1006: The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast. (Yasuaki Sagara). 11:45am - 12:00pm Speaker: Abdualla Al-Rashdan, MD Abstract 1008: Omission of adjuvant radiotherapy is related to an impaired locoregional control and disease-free survival in patients with or without pcr after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials. (David Krug) 12:00pm - 12:10pm Friday

6 Friday Friday 2:30pm - 3:00pm Gastrointestinal (Noncolorectal) Cancer Moderators : Majdi Barakat, MD and Nabil Alloush, MD 2:30pm - 2:45pm Speaker: Fadi Farahat, MD Abstract 4005: Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pnet), CALGB (Alliance). (Matthew H. Kulke) 2:45pm - 3:00pm Speaker: Kholoud Al-qasem, MD Abstract 4000: Phase 3, randomized, double-blind, multicenter, placebo-controlled trial of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) as first-line first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-1 study. (David Cunningham) 3:00pm - 3:40pm Gastrointestinal (Colorectal) Cancer Moderators : Rasmi Mubaideen, MD, and Ghadeer Abdeen, MD 3:00pm - 3:15pm Speaker: Abdulmajeed Dayyat, MD Abstract 3500: A multi-center randomized controlled trial of mfolfox6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results. (Yanhong Deng) 3:15pm - 3:30pm Speaker: Lina Marei, MD Abstract 3503: Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG (Alliance). Abstract 3504: Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study. (Simer Bains). 3:30pm - 3:40pm 3:40pm - 4:00pm

7 Friday 4:00pm - 4:30pm 8:00pm -10:00pm Dinner Melanoma, Skin Cancer Moderators : Salah Halasseh, MD and Sameer Yaser, MD 4:00pm - 4:15pm Speaker: Luqman Soliman, MD Abstract LBA1: CheckMate 067: A phase III randomized double-blind study of nivolumab monotherapy or NIVO combined with ipilimumab versus IPI monotherapy in previously untreated patientswith advanced melanoma. (Jedd D. Wolchok). Abstract 9005 : Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. (Adil Daud) 4:15pm - 4:30pm Speaker: Mahmoud Al Masri, MD Abstract 9001: Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma. (Andrew J Hayes) Abstract LBA9002: Survival of SLNB positive melanoma patients with and without complete lymph node dissection: A multicenter randomized DECOG trial. (Ulrike Leiter). 9:00am - 10:00am Head and Neck Cancer Moderators : Adnan Qasem, MD and Hazem Abdulelah, MD 9:00 am - 9:15am Speaker: Nader Al-Bsoul, MD Abstract LBA3: Elective versus therapeutic neck dissection in the clinically node nega tive early oral cancer: A Randomised control trial (RCT). (Anil D'Cruz). 9:15am - 9:30am 9:30am - 9:45am 9:45am - 10:00am Speaker: Areej Abu Sheikha, MD Abstract 6009: PET-NECK: A multicenter randomized phase III controlled trial (RCT) comparing PET-CT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT). (Hisham Mohamed Mehanna). Speaker: Issa Mohamad, MD Abstract 6000: Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. (Lillian L. Siu) Saturday August 01

8 Saturday August 01 Saturday August 01 10:00am - 10:35am 10:35am - 11:00am Genitourinary (Prostate) Cancer Moderators : Faeq Madanat, MD and Mohammad Salameh, MD 10:00am - 10:20am Speaker: Basel Al Haj Ala, MD Abstract 5001: Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT ). (Nicholas David James). Abstract 5007: TROG and VCOG PR 01-03: The "Timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial. (Gillian M.Duchesne). 10:20am - 10:35am Speaker: Belal Alhawwari, MD Abstract 5006: Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial NCT (Christian Carrie) 11:00am - 12:00pm Lymphoma and Plasma Cell Disorders Moderators : Ahmad Othman, MD and Lina Marei, MD 11:00am - 11:15am Speaker: Kamal Al-rabi, MD Abstract LBA8502: GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-hodgkin lymphoma. (Laurie Helen Sehn) 11:15am - 11:45am Speaker: Sameer Yaser, MD Abstract 8508: ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (Sagar Lonial) Abstract LBA8512: Phase 2 study of daratumumab (DARA) monotherapy in patients with 3 lines of prior therapy or doublerefractory multiple myeloma (MM): MMY2002 (Sirius). (Sagar Lonial). 11:45am -12:00pm

Jordanian Oncology Society Organizing Committee Sana Al Sukhun, MD, MSc Sameh Hashem, MD Mohammad Salameh, MD Mahmoud Al Masri, MD Fayez Tbeishat, MD Faeq Madanat, MD Salah Halasseh, MD Guest Faculty

Dayyat, MD - Jordan Adnan Qasem, MD - Jordan Ahmad Othman, MD - Jordan Ahmad Telfah, MD - Jordan Areej Abu Sheikha, MD - Jordan Basel Al Haj Ali, MD - Jordan Belal Alhawwari, MD - Jordan Faeq

Marei, MD - Jordan Mahmoud Al Masri, MD - Jordan Majdi Barakat, MD - Jordan Mohammad Salameh, MD - Jordan Mohammed Basem Hamdan, MD - Jordan Nabil Alloush, MD - Jordan Nader Al-Bsoul, MD - Jordan

9 Jordanian Oncology Society Organizing Committee Sana Al Sukhun, MD, MSc Sameh Hashem, MD Mohammad Salameh, MD Mahmoud Al Masri, MD Fayez Tbeishat, MD Faeq Madanat, MD Salah Halasseh, MD Guest Faculty Rolf Stahel, MD - Switzerland Fadi Farhat, MD - Lebanon Luqman Soliman, MD - Iraq Tahseen Al-Rubaie, MD - Iraq Local Faculty Abdallah Abbadi, MD - Jordan Abdualla Al-Rashdan, MD - Jordan Abdulmajeed Dayyat, MD - Jordan Adnan Qasem, MD - Jordan Ahmad Othman, MD - Jordan Ahmad Telfah, MD - Jordan Areej Abu Sheikha, MD - Jordan Basel Al Haj Ali, MD - Jordan Belal Alhawwari, MD - Jordan Faeq Madanat, MD - Jordan Fayez Tbeishat, MD - Jordan Ghadeer Abdeen, MD - Jordan Hazem Abdulelah, MD - Jordan Issa Mohamad, MD - Jordan Kamal Al-rabi, MD - Jordan Kholoud Al-qasem, MD - Jordan Lina Marei, MD - Jordan Mahmoud Al Masri, MD - Jordan Majdi Barakat, MD - Jordan Mohammad Salameh, MD - Jordan Mohammed Basem Hamdan, MD - Jordan Nabil Alloush, MD - Jordan Nader Al-Bsoul, MD - Jordan Rasmi Mubaideen, MD - Jordan Salah Abbasi, MD - Jordan Salah Halasseh, MD - Jordan Sameer Yaser, MD - Jordan Sameh Hashem, MD - Jordan Sami Khatib, MD - Jordan Sami Rabadi, MD - Jordan Sana Al Sukhun, MD, MSc - Jordan

Roche Investor Relations ASCO Planner 2015

Roche Investor Relations ASCO Planner 2015 Saturday, May 30 Session Title: Developmental Therapeutics Immunotherapy Poster Board: #341 Molecular, immune and histopathological characterization of NSCLC